Page 99 - 2022-12-中国全科医学

·1504· http://www.chinagp.net E-mail:zgqkyx@chinagp.net.cn

oncology［J］. J Natl Compr Canc Netw，2019，17（8）：977- Curr Drug Targets，2014，15（1）：124-135. DOI：
1007. DOI：10.6004/jnccn.2019.0038. 10.2174/13894501113149990210.
［25］WIRZ S，NADSTAWEK J，ELSEN C，et al. Laxative management ［38］BANTEL C，TRIPATHI S S，MOLONY D，et al. Prolonged-
in ambulatory cancer patients on opioid therapy：a prospective， release oxycodone/naloxone reduces opioid-induced constipation and
open-label investigation of polyethylene glycol，sodium picosulphate improves quality of life in laxative-refractory patients：results of an
and lactulose［J］. Eur J Cancer Care（Engl），2012，21（1）： observational study［J］. Clin Exp Gastroenterol，2018，11：57-
131-140. DOI：10.1111/j.1365-2354.2011.01286.x. 67. DOI：10.2147/CEG.S143913.
［26］TWYCROSS R G，MCNAMARA P，SCHUIJT C，et al. Sodium ［39］LENG X，ZHANG F，YAO S，et al. Prolonged-release（PR）
picosulfate in opioid-induced constipation：results of an open- oxycodone/naloxone improves bowel function compared with
label，prospective，dose-ranging study［J］. Palliat Med， oxycodone PR and provides effective analgesia in Chinese patients
2006，20（4）：419-423. DOI：10.1191/0269216306pm1135oa. with non-malignant pain：a randomized，double-blind trial［J］.
［27］DIPALMA J A，CLEVELAND M B，MCGOWAN J，et al. Adv Ther，2020，37（3）：1188-1202. DOI：10.1007/s12325-
A comparison of polyethylene glycol laxative and placebo for 020-01244-x.
relief of constipation from constipating medications［J］. ［40］ZHANG Y Y，ZHOU R，GU W J. Efficacy and safety of
South Med J，2007，100（11）：1085-1090. DOI： methylnaltrexone for the treatment of opioid-induced constipation：
10.1097/SMJ.0b013e318157ec8f. a meta-analysis of randomized controlled trials［J］. Pain Ther，
［28］EMMANUEL A，JOHNSON M，MCSKIMMING P，et al. Laxatives 2021，10（1）：165-179. DOI：10.1007/s40122-021-00237-0.
do not improve symptoms of opioid-induced constipation：results of ［41］CAMILLERI M，HALE M，MORLION B，et al. Naldemedine
a patient survey［J］. Pain Med，2017，18（10）：1932-1940. improves patient-reported outcomes of opioid-induced constipation
DOI：10.1093/pm/pnw240. in patients with chronic non-cancer pain in the COMPOSE Phase
［29］PAPPAGALLO M. Incidence，prevalence，and management 3 Studies［J］. J Pain Res，2021，14：2179-2189. DOI：
of opioid bowel dysfunction［J］. Am J Surg，2001，182（5A 10.2147/JPR.S282738.
Suppl）：11S-18. DOI：10.1016/s0002-9610（01）00782-6. ［42］WILD J，WEBSTER L，YAMADA T，et al. Safety and efficacy
［30］COBO DOLS M，BEATO ZAMBRANO C，CABEZÓN- of naldemedine for the treatment of opioid-induced constipation in
GUTIÉRREZ L，et al. One-year efficacy and safety of naloxegol on patients with chronic non-cancer pain receiving opioid therapy：a
symptoms and quality of life related to opioid-induced constipation subgroup analysis of patients ≥ 65 years of age［J］. Drugs Aging，
in patients with cancer：KYONAL study［J］. BMJ Support Palliat 2020，37（4）：271-279. DOI：10.1007/s40266-020-00753-2.
Care，2021. DOI：10.1136/bmjspcare-2020-002816. ［Online ［43］ENTEREG®（ALVIMOPAN）. Full Prescribing Information［M］.
ahead of print］. Whitehouse Station，NJ：Merck & Co.，Inc，2015.
［31］COBO DOLS M，BEATO ZAMBRANO C，CABEZÓN GUTIÉRREZ ［44］IRVING G，PÉNZES J，RAMJATTAN B，et al. A randomized，
L，et al. Efficacy of naloxegol on symptoms and quality of life related placebo-controlled phase 3 trial（Study SB-767905/013）of
to opioid-induced constipation in patients with cancer：a 3-month alvimopan for opioid-induced bowel dysfunction in patients with
follow-up analysis［J］. BMJ Support Palliat Care，2021，11（1）： non-cancer pain［J］. J Pain，2011，12（2）：175-184. DOI：
25-31. DOI：10.1136/bmjspcare-2020-002249. 10.1016/j.jpain.2010.06.013.
［32］LEMAIRE A，POINTREAU Y，NARCISO B，et al. Effectiveness ［45］JANSEN J P，LORCH D，LANGAN J，et al. A randomized，
of naloxegol in patients with cancer pain suffering from opioid- placebo-controlled phase 3 trial（Study SB-767905/012）of
induced constipation［J］. Support Care Cancer，2021. DOI： alvimopan for opioid-induced bowel dysfunction in patients with
10.1007/s00520-021-06299-2. ［Online ahead of print］. non-cancer pain［J］. J Pain，2011，12（2）：185-193. DOI：
［33］GALLIGAN J J，AKBARALI H I. Molecular physiology of enteric 10.1016/j.jpain.2010.06.012.
opioid receptors［J］. Am J Gastroenterol Suppl，2014，2（1）： ［46］LONG D D，ARMSTRONG S R，BEATTIE D T，et al. Discovery
17-21. DOI：10.1038/ajgsup.2014.5. of axelopran（TD-1211）：a peripherally restricted μ-opioid
［34］HELM S，TRESCOT A M，COLSON J，et al. Opioid antagonists， receptor antagonist［J］. ACS Med Chem Lett，2019，10（12）：
partial agonists，and agonists/antagonists：the role of office-based 1641-1647. DOI：10.1021/acsmedchemlett.9b00406.
detoxification［J］. Pain Physician，2008，11（2）：225-235. ［47］CRYER B，KATZ S，VALLEJO R，et al. A randomized study of
［35］DEPRIEST A Z，MILLER K. Oxycodone/Naloxone：role in lubiprostone for opioid-induced constipation in patients with chronic
chronic pain management，opioid-induced constipation，and noncancer pain［J］. Pain Med，2014，15（11）：1825-1834.
abuse deterrence［J］. Pain Ther，2014，3（1）：1-15. DOI： DOI：10.1111/pme.12437.
10.1007/s40122-014-0026-2. ［48］BRENNER D M，ARGOFF C E，FOX S M，et al. Efficacy and
［36］BURNESS C B，KEATING G M. Oxycodone/Naloxone prolonged- safety of linaclotide for opioid-induced constipation in patients
release：a review of its use in the management of chronic pain while with chronic noncancer pain syndromes from a phase 2 randomized
counteracting opioid-induced constipation［J］. Drugs，2014，74 study［J］. Pain，2020，161（5）：1027-1036. DOI：
（3）：353-375. DOI：10.1007/s40265-014-0177-9. 10.1097/j.pain.0000000000001754.
［37］LEPPERT W. Oxycodone/naloxone in the management of ［49］SLOOTS C E，RYKX A，COOLS M，et al. Efficacy and safety of
patients with pain and opioid-induced bowel dysfunction［J］. prucalopride in patients with chronic noncancer pain suffering from